Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Merger or Acquisition (September 2023)
10 slides from Coloplast A/s Class B's merger presentation, Sep 4, 2023
Slide 1: Coloplast completes the acquisition of Kerecis
Coloplast completes the acquisition of Kerecis Introduction to Fertram Sigurjonsson, founder and CEO of Kerecis September 4, 2023
Slide 2: Disclaimers
Disclaimers This announcement includes forward-looking statements that involve risks, uncertainties, and other factors, many of which are outside of Coloplast's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking
Slide 3: The acquisition of Kerecis was completed on August 31; financial assumptions unchanged
The acquisition of Kerecis was completed on August 31. The financial assumptions presented on July 7, 2023, are unchanged Compelling strategic rationale confirmed Long-term financial guidance confirmed • Shared mission of making life easier for patients by bringing differentiated technologies to the
Slide 4: Introducing Fertram Sigurjonsson, founder and CEO of Kerecis
Introducing Fertram Sigurjonsson, founder and CEO of Kerecis Introduction to Fertram Sigurjonsson • Entrepreneur and inventor • Extensive experience from the MedTech industry, including the prosthetics industry • Invented the use of gently processed cod fish skin for the treatment of wounds and huma
Slide 5: Fish skin – uniquely positioned for wound healing in humans
Fish skin – uniquely positioned for wound healing in humans Kerecis fish-skin technology – gently processed, preserving its similarity to human skin Fish Skin for Human Skin* Epidermis Dermis 100 µm 100 µm Advantages of the fish-skin technology: • High resemblance to human skin: similar three-dimens
Slide 6: Sustained strong growth momentum through proven commercial model and a purpose-driven organisation
Sustained strong growth momentum through proven commercial model and a purpose-driven organisation Kerecis revenue distribution, FY22/23E Sustained strong growth through: By wound type: By care setting: By geography: • Continued strong growth in the US across wound types and care settings Burn Hospi
Slide 7: Coloplast – the right owner to bring Kerecis' technology to many more patients worldwide
Coloplast – the right owner to bring Kerecis’ technology to many more patients worldwide • Category leader in Chronic Care with long-term commitment to the categories and a business model centred around technology and innovation • Shared mission and shared culture built on values of compassion, curi
Slide 8: With a high growth profile and profitability expansion potential, Kerecis is uniquely positioned
With a high growth profile and profitability expansion potential, Kerecis is uniquely positioned to support Coloplast’s long-term value creation Kerecis - financial assumptions Our updated long-term financial guidance will drive continued long-term value creation • FY 2022/23 revenue growth of aroun
Slide 9: Kerecis is a strong fit to Coloplast's investment case
Kerecis is a strong fit to Coloplast’s investment case and a growth asset that will support long-term value creation Coloplast investment case: • Category leadership positions in a long-term growth industry • Strong culture of innovation dedicated to improving patient outcomes through products and s
Slide 10: Making life easier for people with intimate healthcare needs
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding